公开(公告)号：US12089589B2

公开(公告)日：2024-09-17

申请号：US17702586

申请日：2022-03-23

申请人： Hemanext Inc.

发明人： Tatsuro Yoshida ,  Paul Vernucci

IPC分类号： A01N1/02 ,  A61K35/18 ,  A61J1/10 ,  A61L2/08

CPC分类号： A01N1/0242 ,  A01N1/0205 ,  A01N1/0263 ,  A01N1/0278 ,  A01N1/0294 ,  A61K35/18 ,  A61J1/10 ,  A61L2/081 ,  A61L2/082 ,  A61L2202/181 ,  A61L2202/22

摘要： A blood storage system comprising: a collection vessel for red blood cells; an oxygen or oxygen and carbon dioxide depletion device; a storage vessel for red blood cells; tubing connecting the collection vessel to the oxygen or oxygen and carbon dioxide depletion device and the oxygen or oxygen and carbon dioxide depletion device to the storage vessel; and a gamma or X-ray irradiating device is used to irradiate red blood cells stored in the vessel, storing red blood cells under anaerobic conditions.

公开(公告)号：US20240228983A1

公开(公告)日：2024-07-11

申请号：US18264098

申请日：2022-01-30

申请人： Westlake Therapeutics (Hangzhou) Co. Limited

发明人： Xiaofei Gao ,  Xiaoqian Nie ,  Jun Ren ,  Yanjie Huang ,  Xuan Liu ,  Lu Liu

IPC分类号： C12N9/06 ,  A61K35/18 ,  A61P3/00 ,  C12N5/078 ,  C12P21/06

CPC分类号： C12N9/0048 ,  A61K35/18 ,  A61P3/00 ,  C12N5/0641 ,  C12P21/06

摘要： Provided are a red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by a sortase-mediated glycine conjugation or lysine side chain ε-amino group conjugation, and wherein the agent comprises a uric acid degrading polypeptide, a uric acid transporter or the combination; a method for preparing the RBC; and the use of the RBC for preventing or treating a disorder, condition or disease associated with an elevated uric acid level including hyperuricemia or gout.

公开(公告)号：US20240148872A1

公开(公告)日：2024-05-09

申请号：US18417268

申请日：2024-01-19

申请人： Hemanext Inc.

发明人： Samuel O. SOWEMIMO-COKER ,  Jeffrey SUTTON ,  Tatsuro YOSHIDA

IPC分类号： A61K41/17 ,  A61K35/18 ,  A61L2/00

CPC分类号： A61K41/17 ,  A61K35/18 ,  A61L2/0047 ,  A61L2/0076 ,  A61L2/0082 ,  A61L2202/22

摘要： A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

公开(公告)号：US20240122987A1

公开(公告)日：2024-04-18

申请号：US18379740

申请日：2023-10-13

申请人： THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY

发明人： Andrew P. CAP ,  James A. BYNUM ,  Xiaowu WU

IPC分类号： A61K35/19 ,  A61K9/00 ,  A61K31/137 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/472 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/04 ,  A61K38/095 ,  A61K38/36 ,  A61K38/38 ,  A61K47/26 ,  A61P7/04

CPC分类号： A61K35/19 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/472 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/043 ,  A61K38/095 ,  A61K38/363 ,  A61K38/38 ,  A61K47/26 ,  A61P7/04

摘要： A majority of military casualties occur during the pre-hospital period. The cause of death is largely associated with massive traumatic bleeding that leads to organ damage due to sustained hypoxia. Currently, therapeutics are lacking at the point of injury to mitigate hypoxic damage and maintain the survivability of severe hemorrhage prior to reaching medical facilities. This invention addresses that by introducing a method of co-administering prolyl hydroxylase domain inhibitor (PHDi, MK-8617), anti-fibrinolytic agent (tranexamic acid), and bradykinin receptor antagonist (icatibant) as anti-hemorrhage agents in combination with resuscitation fluid treatment with colloid solution of 25% human albumin that has an advantage of relatively small volume requirement to maintain blood volume. In addition, a kit comprising anti-hemorrhage agents that can be easily carried to the battlefield is also provided here. The therapeutic application of those agents on or near the point of injury can stabilize hypoxia inducible factor-1 alpha and enhance blood clot formation, which improves the patient's cellular adaptation to hypoxia and reduce hemorrhage, and thus can decrease organ failure and increase the patient's survivability.

公开(公告)号：US11896673B2

公开(公告)日：2024-02-13

申请号：US17188583

申请日：2021-03-01

申请人： NORTH CAROLINA STATE UNIVERSITY

发明人： Zhen Gu ,  Chao Wang

IPC分类号： A61K38/28 ,  A61K47/54 ,  A61K47/69 ,  C07H13/08 ,  A61K47/60 ,  A61K47/64 ,  A61P3/10 ,  A61K9/00 ,  A61K35/18

CPC分类号： A61K47/549 ,  A61K9/0021 ,  A61K35/18 ,  A61K38/28 ,  A61K47/60 ,  A61K47/64 ,  A61K47/6937 ,  A61P3/10 ,  C07H13/08

摘要： Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

公开(公告)号：US11833175B2

公开(公告)日：2023-12-05

申请号：US17238804

申请日：2021-04-23

申请人： Fenwal, Inc.

发明人： Katherine Radwanski ,  Craig L. Sandford ,  Kyungyoon Min ,  Bryan Blickhan ,  Daniel Lynn ,  Tat Mui

IPC分类号： A61K35/18 ,  A61K45/06 ,  A01N1/02 ,  A61J1/10 ,  B32B27/08 ,  B32B27/30 ,  B32B27/32 ,  A61J1/14 ,  A61J1/00

CPC分类号： A61K35/18 ,  A01N1/0226 ,  A01N1/0263 ,  A01N1/0273 ,  A61J1/00 ,  A61J1/1468 ,  A61K45/06 ,  B32B27/08 ,  B32B27/304 ,  B32B27/32 ,  B32B2270/00 ,  B32B2307/7244 ,  B32B2439/80

摘要： Red blood cell products and compositions are disclosed. The product includes a container made from PVC or a non-PVC material that is substantially free of a phthalate plasticizer but otherwise includes one or more non-phthalate plasticizers or extractable agents. The product includes a RBC concentrate which has been combined with an additive solution for storing the RBCs.

公开(公告)号：US20230365931A1

公开(公告)日：2023-11-16

申请号：US18305876

申请日：2023-04-24

申请人： University of Massachusetts

发明人： MERAV SOCOLOVSKY ,  Ralph Scully ,  Yung Hwang

IPC分类号： C12N5/078 ,  C12N5/0789 ,  A61P7/06 ,  A61K38/17 ,  A61K35/18 ,  A61K35/28

CPC分类号： C12N5/0641 ,  C12N5/0647 ,  A61P7/06 ,  A61K38/1709 ,  A61K35/18 ,  A61K35/28 ,  C12N2501/14 ,  C12N2501/105 ,  C12N2501/39 ,  C12N2501/998 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/22 ,  C12N2501/405

摘要： Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.

公开(公告)号：US11752202B2

公开(公告)日：2023-09-12

申请号：US17720186

申请日：2022-04-13

申请人： Beam Therapeutics Inc.

发明人： Ian Slaymaker ,  Nicole Gaudelli ,  Yi Yu ,  Bernd Zetsche ,  David A. Born ,  Seung-Joo Lee ,  Michael Packer

IPC分类号： A61K38/50 ,  A61P7/06 ,  A61K35/15 ,  A61K35/18 ,  A61K35/28 ,  A61K38/46 ,  C12N5/078 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12N15/90 ,  C07K14/47 ,  A61P7/00 ,  A61K31/7088

CPC分类号： A61K38/50 ,  A61K31/7088 ,  A61K35/15 ,  A61K35/18 ,  A61K35/28 ,  A61K38/465 ,  A61P7/00 ,  A61P7/06 ,  C07K14/4717 ,  C12N5/0641 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12N15/907 ,  C12Y305/04004 ,  C07K2319/09 ,  C12N2310/20 ,  C12N2506/11 ,  C12N2510/00 ,  C12N2800/80

摘要： The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.

公开(公告)号：US20230263832A1

公开(公告)日：2023-08-24

申请号：US18015209

申请日：2021-07-09

申请人： Children's Medical Center Corporation

发明人： Shin-Young Park ,  Leslie E. Silberstein ,  Jina Ryu ,  Min Liu

IPC分类号： A61K35/18 ,  A61P7/02 ,  A61K39/395 ,  A61K38/48 ,  A61K31/4709 ,  A61K31/4439 ,  A61K38/58 ,  A61K31/506

CPC分类号： A61K35/18 ,  A61P7/02 ,  A61K39/3955 ,  A61K38/482 ,  A61K31/4709 ,  A61K31/4439 ,  A61K38/58 ,  A61K31/506 ,  C12Y304/21068 ,  A61K2039/505

摘要： Provided herein, in some aspects, are compositions comprising vasoocclusion-inhibiting agents encapsulated in RBCs and uses thereof for treating blood vessel occlusion (e.g., in Sickle Cell Disease).

公开(公告)号：US20230173095A1

公开(公告)日：2023-06-08

申请号：US17998945

申请日：2021-05-26

申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： Samir MITRAGOTRI ,  Zongmin ZHAO ,  Junling GUO

IPC分类号： A61K47/69 ,  A61K47/68 ,  C12N15/86 ,  A61K48/00 ,  A61K35/18 ,  A61K35/15

CPC分类号： A61K47/6901 ,  A61K47/6803 ,  A61K47/6849 ,  C12N15/86 ,  A61K48/0033 ,  A61K35/18 ,  A61K35/15 ,  C12N2750/14143 ,  C12N2750/14171

摘要： Described herein are functionalizing nanocomplexes comprising one or more polyphenol molecules; and one or more biomolecules. Further described herein are functionalized cells comprising one or more of the nanocomplexes. In some embodiments, the biomolecules can be therapeutic agents and the functionalized cells can be administered to patients to provide improved delivery (e.g., dosing and specificity) of the therapeutic agent.